Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The tear film air-liquid interface is the outermost boundary of the multi-layered tear film that covers the ocular surface. The tear film consists of a superficial lipid layer (including polar and non-polar lipids from the meibomian glands) and a bulk aqueous/mucin layer from the lacrimal gland, with specialized mucins from goblet cells. The air-liquid interface at the surface of the tear film acts as a barrier between the tear film and the external environment, providing lubrication, optical clarity, and protection against evaporation, pathogens, and physical damage. Dysfunction of the tear film at this interface is involved in dry eye disease and ocular surface disorders, but the interface itself is not a molecular therapeutic target nor a single molecular entity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tear film air-liquid interface.